Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HC Surgical SpecialistsSGX:1B1 +1.45%63 EBITDA Margin % is 43.88% as of May. 2026, which is 4% below its 10-year median of 45.93. GuruFocus rates SGX:1B1 with a GF Score™ of 63/100 and a GF Value™ of S$0.30 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, HC Surgical Specialists ranks better than 98.52% on this metric.
HC Surgical Specialists (SGX:1B1) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HC Surgical Specialists EBITDA Margin % Related Terms
HC Surgical Specialists EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:1B1 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, HC Surgical Specialists's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HC Surgical Specialists EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, HC Surgical Specialists's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HC Surgical Specialists's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HC Surgical Specialists (SGX:1B1) has a EBITDA Margin % of 43.88% as of May. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HC Surgical Specialists and its competitors. This is near median its historical median of 45.93. Over the past decade, HC Surgical Specialists' EBITDA Margin % has ranged from 21.55 to 57.55. According to the industry distribution chart, HC Surgical Specialists ranks #3 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 1.5%.
Is HC Surgical Specialists' EBITDA Margin % too high?
HC Surgical Specialists' current EBITDA Margin % of 43.88% is near median its 10-year median of 45.93. Over the past 10 years, this metric has ranged from a low of 21.55 to a high of 57.55. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.96. HC Surgical Specialists' value of 43.88% is 636.2% above this industry median. Based on the distribution chart, HC Surgical Specialists ranks #3 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, HC Surgical Specialists has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HC Surgical Specialists' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, HC Surgical Specialists ranks #3 out of 203 companies for EBITDA Margin %. This places HC Surgical Specialists in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.96. HC Surgical Specialists' value of 43.88% is 636.2% above this benchmark. Historically, HC Surgical Specialists' own EBITDA Margin % has ranged from 21.55 to 57.55 over the past decade. While the company's 10-year median is 45.93 vs. the industry median of 5.96, HC Surgical Specialists has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.96, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HC Surgical Specialists's current EBITDA Margin % of 43.88% is 636.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HC Surgical Specialists and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HC Surgical Specialists's current EBITDA Margin % is 43.88%, which is near median its own 10-year median of 45.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HC Surgical Specialists stock overvalued right now?
Based on GuruFocus' analysis, HC Surgical Specialists (SGX:1B1) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.30, compared to a current price of S$0.35 — trading 16.7% above its estimated fair value. The current EBITDA Margin % is 43.88%, which is near median its 10-year median of 45.93 and 636.2% above the Medical Diagnostics & Research industry median of 5.96. HC Surgical Specialists' overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HC Surgical Specialists (SGX:1B1), the current EBITDA Margin % is 43.88% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HC Surgical Specialists (SGX:1B1) Overvalued in 2026?
Based on GuruFocus' analysis, HC Surgical Specialists stock appears to be overvalued.
The current stock price of S$0.35 is trading 16.7% above its estimated GF Value™ of S$0.30.
GuruFocus considers HC Surgical Specialists to be Modestly Overvalued.
Key valuation signals for SGX:1B1:
EBITDA Margin %: 43.88% (near median its 10-year median of 45.93)
GF Value™: S$0.30 vs. price of S$0.35 (16.7% above fair value)
Industry Position: 636.2% above the Medical Diagnostics & Research median (#3 of 203)
No single metric tells the full story. See the SGX:1B1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HC Surgical Specialists Ltd is a medical services group. The company is engaged in providing endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services. The operating segment of the company is the healthcare segment. Geographically, it operates only in Singapore. The company has its facilities center and clinics at various places in Singapore.
63GF Score
Get the complete analysis for SGX:1B1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1B1 has been successfully added to your 
